P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

Bibliographic Details
Main Authors:	Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquín Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppa, Pauline Baumlin, Linda Lundberg, James Relf, Yuying Xie, Alessia Bottos, Kathryn Humphrey, Lorenzo Falchi
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971412.45898.1a

Similar Items

P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: E. C. Piccione, et al.
Published: (2022-06-01)

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS
by: M. Dickinson, et al.
Published: (2022-06-01)

P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL
by: P. Strati, et al.
Published: (2022-06-01)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
by: K. Rejeski, et al.
Published: (2022-06-01)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
by: P. Derigs, et al.
Published: (2022-06-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

CAR T-Cell Therapy: Paving the Path to a Brighter Future in LBCL
by: Frederick Locke
Published: (2023-03-01)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
by: P. Strati, et al.
Published: (2022-06-01)

Epidemiological Investigation of Pediatric Fractures—A Retrospective Cohort Study of 1129 Patients
by: Xiaoliang Xiao, et al.
Published: (2023-04-01)

S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY
by: A. Sehgal, et al.
Published: (2022-06-01)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
by: C. Giatra, et al.
Published: (2022-06-01)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
by: Alexander D. Heini, et al.
Published: (2022-09-01)

P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY
by: Adrian Minson, et al.
Published: (2023-08-01)

Curated single cell multimodal landmark datasets for R/Bioconductor.
by: Kelly B Eckenrode, et al.
Published: (2023-08-01)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
by: L. I. Gordon, et al.
Published: (2022-06-01)

S227: INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R-POLA-MINI-CHP AND R-MINI-CHOP
by: Mats Jerkeman, et al.
Published: (2023-08-01)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
by: Javier Munoz, et al.
Published: (2023-08-01)

P1179: PROGNOSIS OF PATIENTS WITH AGGRESSIVE REFRACTORY B-NHL TREATED WITH GLOFITAMAB IN REAL CLINICAL PRACTICE
by: Liudmila Fedorova, et al.
Published: (2023-08-01)

Wyrok Wojewódzkiego Sądu Administracyjnego w Szczecinie z dnia 16 marca 2023 r. (II SA/Sz 1129/22) wraz ze zdaniem odrębnym sędziego WSA Arkadiusza Windaka
Published: (2023-01-01)

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
by: Chaoyu Wang, et al.
Published: (2023-03-01)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
by: Anna Sureda, et al.
Published: (2023-08-01)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
by: Ja Min Byun, et al.
Published: (2023-08-01)

SG-APSIC1129: Long-term effect of a bundled care program in reducing central-line–associated bloodstream infections
by: Yingchieh Liu, et al.
Published: (2023-02-01)

Corrigendum to “Changes in genetic trends in US dairy cattle since the implementation of genomic selection” (J. Dairy Sci. 106:1110–1129)
by: F.L. Guinan, et al.
Published: (2023-12-01)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
by: Aaron Trando, et al.
Published: (2023-09-01)

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
by: E. J. Verburg-Baltussen, et al.
Published: (2022-06-01)

1129 TLR2 and IFNγ synergize to enhance CXCL10 production, tumor-infiltrating lymphocytes, and growth control in triple negative breast cancer
by: Ileana S Mauldin, et al.
Published: (2023-11-01)

Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab
by: Nassim Djebli, et al.
Published: (2024-03-01)

Testicular Diffuse Large B-Cell Lymphoma—Clinical, Molecular, and Immunological Features
by: Marjukka Pollari, et al.
Published: (2021-08-01)

Radiologist-Trained and -Tested (R2.2.4) Deep Learning Models for Identifying Anatomical Landmarks in Chest CT
by: Parisa Kaviani, et al.
Published: (2022-07-01)

100 landmarks of the world : iconic landmarks and monuments of the world /
by: Jollands, Beverley, author, et al.
Published: (2011)

P1234: REAL-WORLD EXPERIENCE OF OUTCOMES WITH GLOFITAMAB SALVAGE THERAPY FOR RELAPSE/REFRACTORY B-CELL LYMPHOMA IN TAIWAN: MINIMAL SAFETY CONCERN WITH HEPATITIS B REACTIVATION
by: S.-J. Wu, et al.
Published: (2022-06-01)

Landmarks of jihad /
by: 374020 M. M. Qureshi
Published: (1971)

Landmarks of Perak /
by: Raja Nazrin Shah Ibni Sultan Azlan Muhibbuddin Shah, author 602676, et al.
Published: (2006)

Landmarks of Selangor /
Published: (2003)

Redefining landmarks
by: Lamit, Hasanuddin
Published: (2007)

Redefining landmarks
by: Lamit, Hasanuddin
Published: (2004)

Landmarks of tomorrow
by: Flávio Penteado Sampaio
Published: (1962-01-01)

Chemical Landmarks
by: Leo Merz
Published: (2015-04-01)

Chemical Landmarks
by: Swiss Chemical Society
Published: (2009-03-01)